Synergic effect between 5‑fluorouracil and celecoxib on hypoxic gastric cancer cells Corrigendum in /10.3892/mmr.2021.12332

Zhang,Xiao‑Qian; Sun,Xiu‑E; Liu,Wen‑Dong; Feng,Yu‑Guang; Zhang,Hong‑Mei; Shi,Li‑Hong; Sun,Xiu‑Ning; Li,Yan‑Qing; Gao,Zhi‑Xing

doi:10.3892/mmr.2014.2783

Synergic effect between 5‑fluorouracil and celecoxib on hypoxic gastric cancer cells

Corrigendum in: /10.3892/mmr.2021.12332

Authors:
- Xiao‑Qian Zhang
- Xiu‑E Sun
- Wen‑Dong Liu
- Yu‑Guang Feng
- Hong‑Mei Zhang
- Li‑Hong Shi
- Xiu‑Ning Sun
- Yan‑Qing Li
- Zhi‑Xing Gao
View Affiliations

Affiliations: Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, Blood Bank, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, Department of Pharmacology, Weifang Medical University, Weifang, Shandong 261053, P.R. China, Department of Parasitology, Weifang Medical University, Weifang, Shandong 261053, P.R. China
Published online on: October 27, 2014 https://doi.org/10.3892/mmr.2014.2783
Pages: 1160-1166

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

5‑fluorouracil (5‑FU) is commonly used in the treatment of gastric cancer; however, resistance to this drug occurs under hypoxic conditions. Celecoxib may be used to reverse this resistance. The aim of the present study was to elucidate the inhibitory effects and mechanisms of 5‑FU and celecoxib on the gastric cancer cell line SGC7901 under hypoxic conditions. SGC7901 cells were divided into four groups: Hypoxic control group, 5‑FU group, celecoxib group and 5‑FU/celecoxib combination group. Following treatment, the inhibition rates of cells were determined using an MTT assay. Protein and messenger RNA (mRNA) expression of hypoxia‑inducible factor 2α (HIF‑2α), adenosine triphosphate‑binding cassette sub‑family G member 2 (ABCG2) and octamer binding protein 4 (Oct‑4) were determined using immunohistochemistry, reverse transcription quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis. The results demonstrated that the 5‑FU/celecoxib combination group had a significantly higher inhibition rate than the individually treated 5‑FU and celecoxib groups (P<0.05); inhibition rates were 66.09, 52.61 and 46.1%, respectively. mRNA and protein expression levels of HIF‑2α, ABCG2 and Oct‑4 were significantly lower in the celecoxib and 5‑FU/celecoxib combination groups (P<0.01) compared with those of the hypoxia control and 5‑FU groups. The 5‑FU group demonstrated the highest levels of the respective mRNA and proteins. In conclusion, the results of the present study indicated that celecoxib had anti‑tumor effects, as it was shown to inhibit tumor cell growth via the inhibition of HIF‑2α, ABCG2 and Oct‑4. The 5‑FU/celecoxib combination had a synergic effect on tumor growth inhibition. This therefore suggested that inhibition of HIF‑2α, ABCG2 and Oct‑4 may be a potential method of reducing chemotherapy resistance and enhancing the effectiveness of chemotherapy treatment.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Agboola O: Adjuvant treatment in gastric cancer. Cancer Treat Rev. 20:217–240. 1994. View Article : Google Scholar : PubMed/NCBI
3	Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
4	Cosse JP and Michiels C: Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem. 8:790–797. 2008. View Article : Google Scholar : PubMed/NCBI
5	Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
6	Griffiths EA, Pritchard SA, Welch IM, Price PM and West CM: Is the hypoxia-inducible factor pathway important in gastric cancer? Eur J Cancer. 41:2792–2805. 2005. View Article : Google Scholar : PubMed/NCBI
7	Liu L, Ning X, Sun L, et al: Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 99:121–128. 2008.
8	Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK and Park JG: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res. 10(1 Pt 1): 272–284. 2004. View Article : Google Scholar : PubMed/NCBI
9	Mathew ST, Devi SG, Prasanth VV and Vinod B: Efficacy and safety of COX-2 inhibitors in the clinical management of arthritis: Mini review. ISRN Pharmacol. 2011:4802912011. View Article : Google Scholar : PubMed/NCBI
10	Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 4:431–436. 2003. View Article : Google Scholar
11	Schönthal AH: Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer. 97:1465–1468. 2007. View Article : Google Scholar : PubMed/NCBI
12	Chuang HC, Kardosh A, Gaffney KJ, Petasis NA and Schönthal AH: COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer. 7:382008. View Article : Google Scholar : PubMed/NCBI
13	Yoshida K, Yamaguchi K, Osada S, Kawaguchi Y, Takahashi T, Sakashita F and Tanaka Y: Challenge for a better combination with basic evidence. Int J Clin Oncol. 13:212–219. 2008. View Article : Google Scholar : PubMed/NCBI
14	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
15	Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
16	Mayer A and Vaupel P: Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Adv Exp Med Biol. 789:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
17	Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC and Keith B: HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20:557–570. 2006. View Article : Google Scholar : PubMed/NCBI
18	Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
19	Martin CM, Ferdous A, Gallardo T, Humphries C, Sadek H, Caprioli A, Garcia JA, Szweda LI, Garry MG and Garry DJ: Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. Circ Res. 102:1075–1081. 2008. View Article : Google Scholar : PubMed/NCBI
20	Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Schöler H and Smith A: Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 95:379–391. 1998. View Article : Google Scholar : PubMed/NCBI
21	Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis. 26:495–502. 2005. View Article : Google Scholar
22	Dallas NA, Xia L, Fan F, et al: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhang XQ, Feng YG, Wu MY, Bai HX and Wang XY: The effect of 5-Fu on the ratio of SP cells and the expression of HIF-2α and ABCG2 in gastric cancer SGC7901 cell line under hypoxia. World Chinese Journal of Digestology. 20:1813–1818. 2012.
24	Rosas C, Sinning M, Ferreira A, Fuenzalida M and Lemus D: Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy. Biol Res. 47:272014. View Article : Google Scholar : PubMed/NCBI
25	Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 342:1946–1952. 2000. View Article : Google Scholar : PubMed/NCBI
26	Li M, Lotan R, Levin B, Tahara E, Lippman SM and Xu XC: Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev. 9:545–549. 2000.PubMed/NCBI
27	Kuo CH, Hu HM, Tsai PY, et al: Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. World J Gastroenterol. 15:4907–4914. 2009. View Article : Google Scholar : PubMed/NCBI
28	Rocha FT, Lourenço LG, Jucá MJ, Costa V and Leal AT: Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy. Acta Cir Bras. 24:189–194. 2009. View Article : Google Scholar : PubMed/NCBI
29	Tang C, Liu C, Zhou X and Wang C: Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer. 112:470–474. 2004. View Article : Google Scholar : PubMed/NCBI
30	Dandekar DS, Lopez M, Carey RI and Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer. 115:484–492. 2005. View Article : Google Scholar : PubMed/NCBI
31	Ding H, Han C, Zhu J, Chen CS and D’Ambrosio SM: Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer. 113:803–810. 2005. View Article : Google Scholar
32	Kim N, Kim CH, Ahn DW, et al: Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol. 24:480–487. 2009. View Article : Google Scholar
33	Swamy MV, Herzog CR and Rao CV: Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res. 63:5239–5242. 2003.PubMed/NCBI
34	Erkinheimo TL, Lassus H, Finne P, van Rees BP, Leminen A, Ylikorkala O, Haglund C, Butzow R and Ristimäki A: Elevated cyclooxygenase-2 expression is associated with alteredexpression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res. 10:538–545. 2004. View Article : Google Scholar : PubMed/NCBI
35	Krysan K, Merchant FH, Zhu L, et al: COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J. 18:206–208. 2004.